MX2023006591A - Composiciones y metodos para el tratamiento de enfermedades oculares. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades oculares.

Info

Publication number
MX2023006591A
MX2023006591A MX2023006591A MX2023006591A MX2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treatment
eye diseases
age
Prior art date
Application number
MX2023006591A
Other languages
English (en)
Spanish (es)
Inventor
Ted Yednock
Anita Grover
Lori Taylor
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of MX2023006591A publication Critical patent/MX2023006591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023006591A 2020-12-04 2021-12-03 Composiciones y metodos para el tratamiento de enfermedades oculares. MX2023006591A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063121629P 2020-12-04 2020-12-04
PCT/US2021/061755 WO2022120137A1 (en) 2020-12-04 2021-12-03 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
MX2023006591A true MX2023006591A (es) 2023-08-11

Family

ID=81853584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006591A MX2023006591A (es) 2020-12-04 2021-12-03 Composiciones y metodos para el tratamiento de enfermedades oculares.

Country Status (11)

Country Link
US (1) US20240059765A1 (https=)
EP (1) EP4255485A4 (https=)
JP (1) JP2023551734A (https=)
KR (1) KR20230117192A (https=)
CN (1) CN116782940A (https=)
AU (1) AU2021391800A1 (https=)
CA (1) CA3200976A1 (https=)
CL (1) CL2023001596A1 (https=)
IL (1) IL303289A (https=)
MX (1) MX2023006591A (https=)
WO (1) WO2022120137A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
KR20250006238A (ko) * 2022-04-29 2025-01-10 애넥슨, 인코포레이티드 안구 질환을 치료하기 위한 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) * 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2017091719A1 (en) * 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof

Also Published As

Publication number Publication date
AU2021391800A1 (en) 2023-06-22
CN116782940A (zh) 2023-09-19
CL2023001596A1 (es) 2024-01-19
JP2023551734A (ja) 2023-12-12
EP4255485A4 (en) 2025-05-14
KR20230117192A (ko) 2023-08-07
US20240059765A1 (en) 2024-02-22
CA3200976A1 (en) 2022-06-09
EP4255485A1 (en) 2023-10-11
WO2022120137A1 (en) 2022-06-09
IL303289A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
AR052172A1 (es) Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares
IL286427B2 (en) Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
NZ775964A (en) Animal models, screening methods, and treatment methods for intraocular diseases or disorders
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
WO2019209955A3 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
BR112022005678A2 (pt) Métodos e composições para o tratamento da retinopatia diabética
MX2021008821A (es) Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea.
Robert et al. Collagen cross-linking of the Boston keratoprosthesis donor carrier to prevent corneal melting in high-risk patients
JOP20230133A1 (ar) استخدام منشطات sGC لمعالجة الأمراض العينية
JOP20220259A1 (ar) تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
MX2024013187A (es) Anticuerpos biespecíficos y métodos de tratamiento de las enfermedades oculares
ZA202309651B (en) Compositions and methods for treatment of ocular disease associated with angiogenesis
DOP2024000180A (es) Agentes de interferencia de arn de sarm1
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
MX2022011234A (es) Composiciones y métodos para la salud ocular que comprenden ácidos grasos de cadena muy larga.
MX2021014682A (es) Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
PE20240228A1 (es) Gotas para los ojos para tratar el adelgazamiento de la esclerotica y metodo de cribado para el agente terapeutico del adelgazamiento de la esclerotica
MX2022011235A (es) Composiciones y metodos para la salud ocular que comprenden areds y complejo de vitamina b.
CL2024003281A1 (es) Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos
BR112022003759A2 (pt) Método e uso de pnpp-19 para prevenção e tratamento de doenças oculares
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas